(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 15.9% in 5 sessions from $12.02 at -15.9, to $10.11 at 12:02 EST on Thursday, after four successive sessions in a row of losses. NASDAQ is rising 0.46% to $11,965.50, following the last session’s downward trend.
Novavax’s last close was $10.44, 89.7% under its 52-week high of $101.39.
About Novavax
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -898.2%.
More news about Novavax (NVAX).
